VENTURA COUNTY
HEALTH CARE PLAN

Prior Authorization DRUG Guidelines

FERRIPROX (Deferiprone)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Catherine Sanders, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Ferriprox is an iron-chelating agent with affinity for ferric ion (iron III); binds to ferric ion and forms a 3:1 (deferiprone:iron) complex which is excreted in the urine. Has a lower affinity for other metals such as copper, aluminum, and zinc.

Pre-Authorization Criteria: treatment of chronic transfusional iron overload due to thalassemia syndromes with inadequate response to other chelation therapy.

Note: An FDA-approved patient **Medication Guide**, which is available with the product information and at http://www.fda.gov/downloads/Drugs/DrugSafety/UCM302558.pdf, must be dispensed with this medication.

Dosing: Adult:
Note: Round dose to the nearest 250 mg (or $^1/_2$ tablet). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.
Transfusional iron overload: Oral: Initial: 25 mg/kg 3 times/day (75 mg/kg/day); individualize dose based on response and therapeutic goal; maximum dose: 33 mg/kg 3 times/day (99 mg/kg/day)

Dosing: Pediatric:
Pediatric dosing is currently unabailable or not applicable for this drug.

Dosing: Geriatric:
Refer to adult dosing. Begin at the low end of dosing range.

Dosing: Renal Impairment:
No dosage adjustments are provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment:
No dosage adjustments are provided in the manufacturer's labeling (has not been studied).

Dosing: Adjustment for Toxicity:
ANC <1500/mm^3: Interrupt treatment
ANC <500/mm^3: In addition to treatment interruption, consider hospitalization (and other clinically-appropriate management); do not resume or rechallenge unless the potential benefits outweigh potential risks

Infection: Interrupt treatment; monitor ANC more frequently

Dosage Forms: U.S.:
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Ferriprox: 500 mg [scored]

Generic Equivalent Available: U.S.-No

Administration:
Administer in the morning, at mid day and in the evening. Administration with food may decrease nausea.

Adverse Reactions:
>10%: nausea, chromaturia
Other Serious Less Common Reactions: hypersensitivity reactions, anaphylaxis, Henoch-Schonlein purpura, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia

U.S. BOXED WARNING:
Agranulocytosis/Neutropenia may occur and lead to serious infections and death; neutropenia may precede agranulocytosis; measure ANC at baseline, then q week; interrupt treatment if ANC <1500 cells/mm^3; interrupt treatment if infection develops and monitor ANC more frequently; advise patients to promptly report any symptoms of infection.

References:

1. Ceci A, Baiardi P, Felisi M, et al, "The Safety and Effectiveness of Deferiprone in a Large-Scale, 3-Year Study in Italian patients," *Br J Haematol*, 2002, 118(1):330-6. [PubMed 12100170]
2. Cohen AR, Galanello R, Piga A, et al, Safety and Effectiveness of Long-Term Therapy With the Oral Iron Chelator Deferiprone," *Blood*, 2003, 102(5):1583-7. [PubMed 12763939]
3. Neufeld EJ, "Oral Chelators Deferasirox and Deferiprone for Transfusional Iron Overload in Thalassemia Major: New Data, New Questions," *Blood*, 2006, 107(9):3436-41.
4. www.uptodate.com: Deferiprone: Drug Information
5. www.epocrates.com: Ferriprox Drug Information

REVISION HISTORY:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 3/12/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI